NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, Forecast & News

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) released its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.02. The biotechnology company earned $0.34 million during the quarter, compared to analyst estimates of $0.85 million. Infinity Pharmaceuticals had a negative return on equity of 125.37% and a negative net margin of 1,519.91%. View Infinity Pharmaceuticals' Earnings History.

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Infinity Pharmaceuticals.

Infinity Pharmaceuticals will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 analysts have issued 12 month price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.50. On average, they expect Infinity Pharmaceuticals' stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 168.6% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Infinity Pharmaceuticals.

Press coverage about INFI stock has been trending negative on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Infinity Pharmaceuticals.

Infinity Pharmaceuticals saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 48,300 shares, a decline of 61.2% from the January 30th total of 124,500 shares. Based on an average trading volume of 169,900 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (Clr), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), ImmunoGen (IMGN), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO) and Celldex Therapeutics (CLDX).

Infinity Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.21%), Acadian Asset Management LLC (1.11%), Oxford Asset Management LLP (0.38%), Jacobs Levy Equity Management Inc. (0.24%) and Virtu Financial LLC (0.05%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

INFI stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Infinity Pharmaceuticals.

INFI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC and Acadian Asset Management LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INFI stock can currently be purchased for approximately $1.21.

Infinity Pharmaceuticals has a market capitalization of $69.01 million and generates $22.15 million in revenue each year. The biotechnology company earns $-11,250,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.View Additional Information About Infinity Pharmaceuticals.

The official website for Infinity Pharmaceuticals is http://www.infi.com/.

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]